Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer
- PMID: 30332285
- DOI: 10.2214/AJR.18.20495
Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer
Abstract
Objective: The purpose of this study is to investigate the diagnostic value of various MRI sequences used for whole-body (WB) 18F-fluorocholine (FCH) PET/MRI staging of patients with high-risk prostate cancer (PCa).
Subjects and methods: This analysis is based on data from a prospective study that included 58 patients with untreated high-risk PCa who underwent integrated WB FCH PET/MRI (n = 10) or FCH PET/CT and WB MRI (n = 48). Metastatic sites were recorded. The standard of reference was histopathologic findings or clinical and imaging follow-up, or both. For each MRI sequence (Dixon T1-weighted, turbo inversion recovery magnitude, WB DWI, and gadolinium-enhanced T1-weighted volumetric interpolated breath-hold examination [VIBE]), acquisition time was recorded, and conspicuity of metastatic lesions was qualitatively assessed by two radiologists using a 4-point ordinal scale (0-3).
Results: Total WB acquisition times were 1 minute 25 seconds for Dixon T1-weighted, 15 minutes 7 seconds for turbo inversion recovery magnitude, 16 minutes 33 seconds for WB DWI, and 1 minute 28 seconds for gadolinium-enhanced T1-weighted VIBE. The lesion detection rates were 88.3% (68/77) for Dixon T1-weighted, 94.8% (73/77) for turbo inversion recovery magnitude, 95.2% (40/42) for WB DWI, and 97.4% (75/77) for gadolinium-enhanced T1-weighted VIBE sequences. Moderate or high conspicuity scores were assigned to 62.3% (48/77) of lesions for Dixon T1-weighted, 88.3% (68/77) of lesions for turbo inversion recovery magnitude, 90.5% (38/42) of lesions for WB DWI, and 92.2% (71/77) of lesions for gadolinium-enhanced T1-weighted VIBE sequences. Conspicuity of metastases on gadolinium-enhanced T1-weighted VIBE and WB DWI sequences was higher than that on Dixon T1-weighted sequences (p < 0.0001 and p = 0.0011, respectively).
Conclusion: Metastases from prostate cancer are best detected at DWI or gadolinium-enhanced T1-weighted VIBE sequences. The most time-efficient sequence with the highest lesion detection rate and conspicuity is gadolinium-enhanced T1-weighted VIBE.
Keywords: PET/MRI; conspicuity; prostate cancer; sequence; whole body.
Similar articles
-
Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.J Nucl Med. 2014 Feb;55(2):191-7. doi: 10.2967/jnumed.113.123646. Epub 2013 Dec 5. J Nucl Med. 2014. PMID: 24309383
-
Diagnosing Lung Nodules on Oncologic MR/PET Imaging: Comparison of Fast T1-Weighted Sequences and Influence of Image Acquisition in Inspiration and Expiration Breath-Hold.Korean J Radiol. 2016 Sep-Oct;17(5):684-94. doi: 10.3348/kjr.2016.17.5.684. Epub 2016 Aug 23. Korean J Radiol. 2016. PMID: 27587957 Free PMC article.
-
18F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer.AJR Am J Roentgenol. 2018 Mar;210(3):635-640. doi: 10.2214/AJR.17.18567. Epub 2018 Jan 11. AJR Am J Roentgenol. 2018. PMID: 29323548
-
Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.Top Magn Reson Imaging. 2007 Jun;18(3):193-202. doi: 10.1097/RMR.0b013e318093e6bo. Top Magn Reson Imaging. 2007. PMID: 17762383 Review.
-
Rationale for Modernising Imaging in Advanced Prostate Cancer.Eur Urol Focus. 2017 Apr;3(2-3):223-239. doi: 10.1016/j.euf.2016.06.018. Epub 2016 Jul 15. Eur Urol Focus. 2017. PMID: 28753774 Review.
Cited by
-
Magnetic Resonance Imaging Evaluation of Bone Metastases Treated with Radiotherapy in Palliative Intent: A Multicenter Prospective Study on Clinical and Instrumental Evaluation Assessment Concordance (MARTE Study).Diagnostics (Basel). 2023 Jul 10;13(14):2334. doi: 10.3390/diagnostics13142334. Diagnostics (Basel). 2023. PMID: 37510078 Free PMC article.
-
18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center.Curr Oncol. 2021 Aug 25;28(5):3251-3258. doi: 10.3390/curroncol28050282. Curr Oncol. 2021. PMID: 34449586 Free PMC article.
-
PET/MRI in prostate cancer: a systematic review and meta-analysis.Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):859-873. doi: 10.1007/s00259-020-05025-0. Epub 2020 Sep 8. Eur J Nucl Med Mol Imaging. 2021. PMID: 32901351 Free PMC article.
-
Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.Can Urol Assoc J. 2021 Jun;15(6):162-172. doi: 10.5489/cuaj.7268. Can Urol Assoc J. 2021. PMID: 33661093 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical